Xilio Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.22 Insider Own7.40% Shs Outstand27.42M Perf Week-0.67%
Market Cap78.15M Forward P/E- EPS next Y-2.90 Insider Trans0.00% Shs Float25.44M Perf Month-7.52%
Income-88.20M PEG- EPS next Q-0.89 Inst Own67.90% Short Float / Ratio0.44% / 2.20 Perf Quarter23.95%
Sales- P/S- EPS this Y-13.30% Inst Trans-6.07% Short Interest0.11M Perf Half Y1.72%
Book/sh3.85 P/B0.77 EPS next Y-10.70% ROA-52.60% Target Price9.75 Perf Year-58.91%
Cash/sh4.55 P/C0.65 EPS next 5Y- ROE-65.10% 52W Range1.95 - 8.00 Perf YTD9.67%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-63.12% Beta-
Dividend %- Quick Ratio5.90 Sales past 5Y- Gross Margin- 52W Low51.28% ATR0.29
Employees89 Current Ratio5.90 Sales Q/Q- Oper. Margin- RSI (14)46.88 Volatility8.49% 9.85%
OptionableNo Debt/Eq0.09 EPS Q/Q-10.90% Profit Margin- Rel Volume0.70 Prev Close3.01
ShortableYes LT Debt/Eq0.03 EarningsMar 02 AMC Payout- Avg Volume51.29K Price2.95
Recom1.80 SMA201.11% SMA50-8.23% SMA2007.48% Volume35,789 Change-1.99%
Dec-21-22Initiated Chardan Capital Markets Buy $7
Jan-10-22Initiated H.C. Wainwright Buy $36
Nov-16-21Initiated Raymond James Outperform $31
Nov-16-21Initiated Morgan Stanley Overweight $32
Nov-16-21Initiated Guggenheim Buy $40
Nov-16-21Initiated Cowen Outperform
Mar-02-23 04:05PM
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
09:45AM Loading…
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
07:30AM Loading…
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, discovers and develops tumor-activated immuno-oncology therapies. Its checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 1 clinical trial for patients with advanced solid tumors. The company also develops cytokine programs, which comprises XTX202, a tumor-activated IL-2; and XTX301, an investigational tumor-activated, engineered IL-12 molecule. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.